Many investors were skeptical of biotechs specializing in gene editing three years ago. Though some had made clinical progress, few had launched any product. Since then, there have been more clinical wins and several more launches in this field.

Unfortunately, Intellia Therapeutics (NASDAQ: NTLA) hasn't been one of the top performers in this niche. The biotech's shares are down by 30% over the past year. Is it worth buying Intellia Therapeutics' shares right now? Let's find out.

It's not a great time to be a clinical-stage biotech, which is exactly what Intellia Therapeutics is. Though the company has some promising programs, it generates little revenue and is consistently unprofitable. Still, meaningful progress from its leading candidates could send its stock price soaring, especially as they inch closer to approval.

Continue reading

Source Fool.com